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Abstract
Background: Using gene co-expression analysis, researchers were able to predict clusters of genes with consistent
functions that are relevant to cancer development and prognosis. We applied a weighted gene co-expression
network (WGCN) analysis algorithm on glioblastoma multiforme (GBM) data obtained from the TCGA project and
predicted a set of gene co-expression networks which are related to GBM prognosis.
Methods: We modified the Quasi-Clique Merger algorithm (QCM algorithm) into edge-covering Quasi-Clique
Merger algorithm (eQCM) for mining weighted sub-network in WGCN. Each sub-network is considered a set of
features to separate patients into two groups using K-means algorithm. Survival times of the two groups are
compared using log-rank test and Kaplan-Meier curves. Simulations using random sets of genes are carried out to
determine the thresholds for log-rank test p-values for network selection. Sub-networks with p-values less than
their corresponding thresholds were further merged into clusters based on overlap ratios (>50%). The functions for
each cluster are analyzed using gene ontology enrichment analysis.
Results: Using the eQCM algorithm, we identified 8,124 sub-networks in the WGCN, out of which 170 sub-
networks show p-values less than their corresponding thresholds. They were then merged into 16 clusters.
Conclusions: We identified 16 gene clusters associated with GBM prognosis using the eQCM algorithm. Our results
not only confirmed previous findings including the importance of cell cycle and immune response in GBM, but
also suggested important epigenetic events in GBM development and prognosis.
Background
The rapid development of high throughput gene expres-
sion profiling technology such as microarray and high
throughput sequencing has enabled the development of
many new bioinformatics data analysis methods for identi-
fying disease related genes, characterizing disease subtypes
and discovering gene signatures for disease prognosis and
treatment prediction. For instance, in breast cancer
research, a supervised approach was adopted to select 70
genes as biomarkers for breast cancer prognosis [1,2] and
was successfully tested in clinical settings [3]. However, a
major drawback of such approach is that the selected gene
features are usually not functionally related and hence
cannot reveal key biological mechanisms and processes
behind the difference of the two patient groups.
In order to overcome this issue and identify function-
ally related genes associated with disease development
and prognosis, several approaches have been adopted.
One of such approaches is to use gene co-expression
analysis. For instance, in [4] and [5], we carried out
gene co-expression network analysis for biomarker dis-
covery in different types of cancers.
The goal of gene co-expression network (GCN) analy-
sis is to identify group of genes which are highly corre-
lated in expression levels across multiple samples. The
genes in the same co-expression sub-network are often
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the correlation is usually the correlation coefficient (e.g.,
Pearson correlation coefficient or PCC) between expres-
sion profiles of two genes [6-8]. Then for each dataset, a
weighted graph can be derived with the vertices being
the genes and the weights of the edges being the PCC
values between the two gene expression profiles. How-
ever, many network mining algorithms take only binary
edges by imposing a threshold on the PCC values (i.e.,
two genes are connected by an edge only if the PCC
value between them is higher than a pre-defined thresh-
old) and transforming the network into a sparse
unweighted gene co-expression network (UWGCN). For
instance, in [6], an algorithm called CODENSE was
developed to identify frequent UWGCNs from multiple
datasets and this method has been applied to cancer
biomarker discovery. Issues with the UWGCN approach
include how to determine the threshold of PCC values
a n dt h et h r e s h o l dm a yb et o o rigid to include edges
with weights around that threshold. Thus weighted
GCN (WGCN) methods have been developed.
For WGCN, Stephen Horvath’s group has developed a
series of methods for identifying gene clusters which are
highly correlated using hierarchical clustering based
approach [7,9,10]. This method was applied to identify
disease associated genes such as the ASPM gene in glio-
blastoma [9]. However, there are several drawbacks of
using the hierarchical cluster i n ga p p r o a c h .F i r s t ,i td o e s
not allow direct control over the intracluster connectivity
such that the vertices within a cluster have high correla-
tions on average. Second, the clustering approach does
not allow shared genes between two sub-networks even
though in biology, many genes have multiple functions
and can be shared by multiple functional groups and
dense sub-networks. Finally, clusters identified using this
approach are often large (e.g., more than 100 genes), thus
smaller gene networks which contain subtle functional
information may not be detected.
In this paper, we take advantage of the dense sub-net-
work finding method in the graph mining community
and apply it to mine functional networks using the
WGCN approach to identify dense co-expression sub-
networks in glioblastoma. Specifically, using The Cancer
Genome Atlas (TCGA) data sets, we identified co-
expressed sub-networks (sub-networks for short in the
following) for genes then we tested if these sub-net-
works can be used as features to separate patients into
groups with different survival times. Using this
approach, we identified 16 gene networks associated
with GBM prognosis. Our results not only confirmed
previous findings in GBM, but also suggested important
epigenetic events (histone acetylation) in GBM develop-
ment and prognosis.
Methods
Gene expression dataset for GBM
We downloaded gene expression data from the Cancer
Genome Atlas (TCGA) project webpage (http://cancer-
genome.nih.gov, downloaded on 11/24/2010) for all
GBM patients with gene expression data generated using
Affymetrix HU133 Genechip. We also downloaded all
available public clinical data including survival informa-
tion. In total, we selected 361 patients with complete
data (i.e., each has one set of gene expressions, one set of
microRNA expressions, and public clinical information).
Among them, 345 have a valid vital status (i.e., either
LIVING or DECEASED) and they are good for survival
tests. The gene expression data were normalized using
RMA normalization as described in the TCGA NCI Wiki.
Building WGCN for genes
After normalization a total of 12,042 unique genes were
available. PCC were computed between every pair of
genes. We then set the genes to be the vertices of the
WGCN with the absolute values of PCC (|PCC|) being
weights of the edges.
Identify quasi-cliques in the WGCNs
W ef i r s td e f i n et h ed e n s i t yo faw e i g h t e dn e t w o r kw i t h
N vertices with wij being the weight, normalized
between 0 and 1, between vertices vi and vj (i = 1, 2,...,
N, j = 1, 2,..., N, and i≠j )a sd =
N−1
i=1
N
j=i+1 wij
N(N − 1)/2
For mining densely connected networks in the
WGCN, our approach is based on an existing algorithm
previously developed for mining weighted networks [11].
Different from many graph mining approaches (e.g.,
[12]) that focus on unweighted graphs, the algorithm of
[11] targets primarily at identifying dense components
(or sub-networks) in a weighted graph (i.e., each edge
has a weight), although it is called Quasi-Clique Merger
(QCM). To mine dense-sub-networks in a gene-coex-
pression network, we slightly revise the original QCM
algorithm by removing the hierarchical construction
which does not contribute to our dense-sub-network
finding, and changing the new search start condition
from checking vertex coverage to checking edge cover-
age to ensure that each edge with its weight no less
than the weight threshold (g times the maximum edge
weight) will be covered by at least one dense-sub-net-
work. The revised algorithm is sketched below:
Algorithm 1 eQCM (edge-covering Quasi-Clique
Merger, a revised version of QCM [11]. Input G=(V,
E), g, l,t ,b, Output: C )
1: Sort edges in E in descending order of their
weights;
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Page 2 of 82: for i=1 : μ {eμ is the last edge in the above sorted
list with weight ≥g·e1}
3: if ei is an edge in any sub-network in C
4: continue;
5: endif
6: C = V(ei); U = V \ V(ei);
7: while max{vÎU}(contribute(v,C)) ≥ threshold
8: C = C ∪ {v};
9: U = U \ {v};
10: endwhile
11: C = C ∪ {C};
12: endfor
13: Merging highly overlapped sub-networks in C with
respect to b;
14: Output C ;
To be consistent with the original QCM algorithm
[11], contribute (v, C) is defined as the ratio of the edge
weight increase of G(C) on adding the vertex v, over the
size of C, and threshold is

1 −
1
2λ(|C| + t)

*density
(G(C)), which is determined by the input parameter l,t ,
the size of C, and the density of the sub-network
induced by C. Readers may refer to [11] for additional
details. The last second step (merging) is the step 4 in
t h eo r i g i n a lQ C Ma l g o r i t h m .S i n c ew ea r ei n t e r e s t e di n
identifying gene sub-networks with potential consistent
functions, we select only the sub-networks with at least
10 genes to facilitate gene function enrichment analysis.
Survival test for identified networks
For each sub-network, we test if the genes in it can be
used as potential prognostic markers for predicting
GBM survival. For a network with k genes, we extract
the expression values for them for all patients and use
them as the feature vectors for patients. The patients
are then divided into two groups using the unsupervised
K-means clustering algorithm (K = 2, 100 time repli-
cates, correlation distance measure).
The survival times for the two patient groups are
plotted in Kaplan-Meier curves and the difference
between the two groups is tested using log-rank test
(code at http://www.mathworks.com/matlabcentral/
fileexchange/20388). P-values for the log-rank tests for
all the identified networks are recorded.
Select representative sub-networks with significant
p-values
Since many of the identified networks have large over-
laps, we cannot directly apply multiple test compensa-
tion method such as the Bonferroni correction as the
tests are not independent and such correction would be
too conservative. Instead, we design a randomized test
to determine the false discovery ratio (FDR) for selecting
significant sub-networks.
For an N-gene sub-network, we randomly selected a
list of genes from the entire gene list in the dataset such
that the expected length of the selected gene list is N.
Then we repeat the survival test process as described
above. Such random test is repeated 1000 times. The
lower 5
th percentile of the 1000 p-values is used as the
threshold for p-value for selecting sub-networks with
significant prognostic power. Since we have a large
number of sub-networks and cannot carry out 1000 ran-
dom tests for every possible N, we do such random tests
for N = 1*10
1,2 * 1 0
1,...9*10
1,1 * 1 0
2,2 * 1 0
2,... and the
p-value thresholds are p10,p 20,..., p100,p 200,... Our results
show that the p-value thresholds are close when N are
close. Thus for a sub-network with size N’, its p-value
for survival test is compared to pi where
i =

N 
10 lgN  

∗ 10 lgN  to determine if it is significant.
For example, a gene list with 28 genes compares its
p-value to p20, and a gene list with 250 genes compare
its p-value to p200.
We also noticed that many of the selected significant
sub-networks have substantial overlaps and they form
exclusive clusters. To identify such clusters, we itera-
tively merge networks with substantial overlaps (i.e, the
overlap ratio r between two networks is larger than
50%) into clusters. The overlap ratio between two sub-
networks G1=(V1,E 1)a n dG 2=(V2,E 2) is defined as
|V1 ∩ V2|
min(|V1|,|V2|)
Then we pick the sub-network with the
lowest p-value in each cluster as the representative sub-
network for further analysis.
For the representative sub-networks, we used TOPP-
Gene (http://toppgene.cchmc.org) for gene ontology and
pathway enrichment analysis without Bonferroni
correction.
Results
Using the eQCM algorithm (g =0 . 7 ,l =1 ,t=1 ,b =
0.99999), we identified 8,124 sub-networks with at least
ten vertices in the WGCN. The survival tests were then
carried out on them and 866 show p-values less than
0.05. In addition, random tests were performed to
obtain p10,p 20,..., p90,p 100,..., p500 and all of them are
smaller than 0.01. 170 sub-networks with significant p-
values were selected and their densities range from
0.612 to 0.862. Then sub-networks with substantial
overlaps (overlap ratio > 50%) were iteratively merged
into sixteen clusters. The representative sub-networks
f o re v e r yc l u s t e ra n dt h e i rp - v a l u e sa n de n r i c h e dG O
functions are shown in Table 1. For cluster 1, the repre-
sentative sub-network is highly enriched with genes
involved in extracellular matrix organization (p =8 . 2 2×
10
-7) which also engage in many important biological
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Page 3 of 8Table 1 List of representative networks with log-rank test p-values.
Cluster
#
#o f
unique
genes
Representative
network size
Log-rank test
p-value
Top enriched GO terms Member genes of the representative network
1 284 11 5.7 × 10
-5 BP: extracellular matrix organization
(8.22 × 10
-7)
BP (entire cluster): immune system process
(1.01 × 10
-46)
MF: enzyme inhibitor activity (2.28 × 10
-7)
CC: proteinacious extracellular matrix
(7.32 × 10
-7)
CLIC1, ILK, LGALS1, LGALS3, ANXA2, TIMP1, ANXA2P2, IQGAP1, EMP3, CAST, HEXB
2 43 22 1.31 × 10
-4 BP: chromatin organization (1.91 × 10
-4)
MF: deoxycytidyltransferase activity
(2.28 × 10
-7)
CC: nucleoplasm (7.75 × 10
-5)
C10orf18, TAF5, SIRT1, FMR1, FBXO11, TCERG1, CXorf45, CASP8AP2, ARID4B,
JMJD1C, TAF2, ELF2, CENPC1, ZNF131, NUP153, SUZ12, SR140, ATAD2B, HISPPD1,
REV1, PMS1, ZCCHC11
3 34 16 2.21 × 10
-4 BP: RNA processing (6.60 × 10
-5)
MF: poly(A)-specific ribonuclease activity
(1.50 × 10
-3)
CC: nuclear speck (9.97 × 10
-5)
USP52, ZCCHC11, FNBP4, CROP, NKTR, SFRS18, RBM6, RBM5, CCNL2, C21orf66,
DMTF1, WSB1, CDK5RAP3, ZNF692, LOC440350, LOC339047
4 27 25 4.52 × 10
-4 BP: translation (2.06 × 10
-5), ncRNA metabolic process
(4.01 × 10
-4)
MF: structural constituent of ribosome
(5.92 × 10
-5)
CC: ribonucleoprotein complex
(2.03 × 10
-7)
RPP30, UCK2, BUB3, SMNDC1, SAR1A, MRPS16, GLRX3, TIMM23, UTP11L, HCCS,
POLR3C, EIF2B3, MRPL9, SNRPD1, TFB2M, SUMO1, FASTKD3, HSPA14, DUSP11,
ATPBD1C, MRPS15, MED28, GTF2B, MRPL22, POLE3
5 15 15 6.19 × 10
-4 BP: RNA processing (2.18 × 10
-10), RNA splicing
(7.93 × 10
-8)
MF: RNA binding (2.00 × 10
-12)
CC: heterogeneous nuclear ribonucleoprotein complex
(1.22 × 10
-12)
JARID1B, RBM12, ADNP, CPSF6, HNRPA3, ILF3, CTCF, HNRPD, HNRNPA0, SART3,
HNRPDL, SFPQ, HNRNPR, TARDBP, TLK2
6 35 27 0.0016 BP: chromatin modification (1.64 × 10
-9), histone
acetylation (5.73 × 10
-6)
MF: transcription activator activity
(1.18 × 10
-5)
CC: nucleolus (1.39 × 10
-8)
BAHCC1, CHD7, PHF2, TOP2B, TCF4, MYST3, SETD5, POGZ, BRD3, MED13, BPTF,
GPATCH8, TARDBP, ILF3, HNRNPR, NASP, MDC1, ARID1A, TRIM33, CTCF, HNRPA3,
RBM10, YLPM1, SMARCA4, SART3, SFRS8, EP400
7 12 12 0.002747 BP: pentose-phosphate shunt , oxidative branch
(1.94 × 10
-3)
MF: 6-phosphoglucono-lactonase activity
(1.29 × 10
-3)
CC: ribosome (7.42 × 10
-3)
PGLS, TMED1, CD320, MRPL4, RFXANK, TMEM161A, CLPP, STX10, TMEM147, EIF3G,
C19orf56, UBA52
8 39 32 0.002782 BP: translation (8.30 × 10
-7)
MF: structural constituent of ribosome (8.92 × 10
-9)
CC: ribosome (1.59 × 10
-9), mitochondrion
(2.47 × 10
-6)
COMMD3, HSBP1, ZNF32, SUPT4H1, NFU1, LYRM4, RPS3A, RPS7, SNRPG, HAX1,
MED28, UXT, MRPL22, FAM96B, UQCRQ, HBXIP, UBL5, MRPS15, NDUFA2, GTF2B,
DUSP11, PSMA5, GTF2A2, PSMB4, ATP5F1, MRPL13, ATPBD1C, MRPL46, MRPL11,
MRPS7, WDR61, BNIP1
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8Table 1 List of representative networks with log-rank test p-values. (Continued)
9 25 25 0.003697 BP: RNA processing (1.06 × 10
-3), mitotic cell cycle
(1.66 × 10
-3)
MF: eukaryotic initiation factor 4G binding (1.29 × 10
-3),
RNA binding (4.08 × 10
-3)
CC: chromosomal part (2.64 × 10
-3)
DDX52, PRPSAP2, YWHAQ, ORC4L, MOBKL3, MYNN, CENPQ, C11orf73, MIS12,
HMGN4, C14orf104, FASTKD3, SNRPD1, C4orf27, SFRS3, SUMO1, GIN1, FLJ13611,
THAP1, ATPBD1C, DUSP11, EIF4E, PIGF, RY1, NIF3L1
10 14 14 0.004707 BP: nuclear-transcribed mRNA catabolic process
(1.82 × 10
-3)
MF: RNA binding (3.02 × 10
-3)
CC: BRISC complex (2.94 × 10
-3)
DDX50, DIP2C, KIAA0157, KIAA1128, KIAA1279, LARP5, PAPD1, RAB11FIP2, SHOC2,
TNKS2, UPF2, WAC, WDR37, ZMYND11
11 22 16 0.005489 BP: type I interferon-mediated signalling
(4.49 × 10
-14) pathway, immune system process
(1.79 × 10
-11)
MF: MHC class I receptor activity
(4.94 × 10
-10)
CC: MHC class I protein complex
(1.80 × 10
-9)
CASP1, CASP4, PLSCR1, NMI, SP100, SP110, TRIM22, TRIM6-TRIM34, TRIM21, IFI35,
PSMB9, PSMB8, HLA-F, HLA-B, HLA-C, HLA-E
12 12 12 0.005663 BP:-
MF: sequence-specific DNA binding transcription factor
activity (2.43 × 10
-2)
CC:-
ZNF134, ZNF180, ZNF211, ZNF222, ZNF223, ZNF228, ZNF230, ZNF304, ZNF419,
ZNF45, ZNF606, ZNF8
13 21 21 0.006774 BP: mitotic cell cycle (6.43 × 10
-5)
MF: RNA trimethylguanosine synthase activity
(1.13 × 10
-3)
CC: nucleoplasm (4.08 × 10
-4)
EED, POLD3, ELF2, CENPC1, HISPPD1, ZNF131, RBM12, CEP57, NOL11, COIL,
NUP160, CEP76, ZNF140, ZNF143, TDG, TAF11, FASTKD3, TGS1, EXOSC9, YTHDF2,
SAE2
14 18 18 0.006858 BP: arginine biosynthetic process via orthithine
(9.69 × 10
-4)
MF: argininosuccinate lyase activity
(9.67 × 10
-4)
CC: organelle envelope (4.11 × 10
-3)
ASL, ZMYM6, RAB32, CD58, MOBKL1B, TRAM1, CD164, RER1, CCDC109B, CLIC1,
CASP4, SQRDL, SERPINB1, MR1, CASP1, CAPG, MGAT4A, ANXA4
15 22 22 0.007708 BP: multicellular organismal movement
(4.97 × 10
-4)
MF: ATP-dependent helicase activity (2.22 × 10
-4)
CC: endopeptidase Clp complex
(1.10 × 10
-3)
SEC24A, TMF1, KIAA0372, CLCC1, DHX29, SLC30A5, VPS54, CHD1, RPS6KB1,
HISPPD1, ETAA1, CENPC1, CLPX, C1orf9, ZNF131, KLHL20, REV1, ZC3H7A, DDX46,
NUP153, SMCHD1, PPWD1
16 15 15 0.008207 BP: ribulose-phosphate 3-epimerase activity
(8.069 × 10
-4)
MF: mRNA 3’-end processing
(1.429 × 10
-3)
CC: SPOTS complex (1.574 × 10
-3)
C15orf15, SELT, COMMD10, UBE2A, TMED2, CNOT8, NMD3, MRPL42, BZW1,
NUDT21, SPTLC1, DCTN4, YIPF5, RPE, C20orf30
The p-values associated with the GO terms are based on Fisher’s exact tests without Bonferroni correction (http://toppgene.cchmc.org).
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8processes such as cell-cell signaling and immune
responses. Indeed, the entire set of genes in cluster 1
are highly enriched with immune system process genes
(p =1 . 0 1×1 0
-46). Figure 1 shows examples of
the Kaplan-Meier curves for some of the representative
sub-networks in separating the patients using the
unsupervised K-means algorithm, and heatmaps for
these sub-networks.
Discussion
In this paper, we carried out a co-expression analysis on
GBM gene expression data to screen for biological
Figure 1 Kaplan-Meier curves and heatmaps for two groups of patients with significantly different survival times identified using
three networks. Top: Left - The Kaplan-Meier curve for the patients separated using the immune response network #1. Right - The heatmap of
the gene expression values for the genes in the representative network #1. The vertical white line indicates the separation between short
survival (left to the white line) and long survival (right to the white line) groups. The density of the representative network is 0.6928 and the p-
value is 5.7 × 10
-5. Middle: The Kaplan-Meier curve and heatmap for the chromatin modification network #6. The density of the representative
network is 0.6951 and the p-value is 0.0016. Bottom: The Kaplan-Meier curve and heatmap for the mitotic cycle network #13. The density of the
representative network is 0.6764 and the p-value is 0.006774.
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Page 6 of 8processes involved in patient prognosis. In previous stu-
dies, using co-expression analysis based on clustering
algorithm, ASPM has been identified as an important
t a r g e tg e n ei nG B M[ 9 ] .A S P Mi si n v o l v e di nc e l lc y c l e
and mitosis functions and many networks with ASPM
were identified in our study. We also identified a mitosis
related sub-network with a significant p-value in our
study (sub-network #13 in Table 1). Besides cell cycle
networks, immune response networks also prove to be
critical in GBM development as shown in sub-networks
#1 and #11, which is consistent with the previous report
on the importance of immune and inflammation genes
in GBM [13]. As shown in Figure 1, genes in sub-net-
work #1 show higher expression levels in the short sur-
vival group. Since a characteristic of GBM is its high
metastasis occurrence and extracellular and immune
genes play important roles in metastasis, the genes in
this group may be potential targets for treatment for
reducing metastasis. An interesting observation is that
two sub-networks (#2 and #6) related to chromatin
modification are identified. Particularly in sub-network
#6, histone acetylation genes are highly enriched includ-
ing well known chromatin modification genes such as
CTCF [14] and EP400 [15]. The expression levels of
these genes show down-regulation in the short survival
group which indicates a possibly reduced histone acety-
lation activity. Histone acetylation is an important epige-
netic event [16] and our findings suggest that
epigenetics may play an important role in GBM devel-
opment and prognosis and ChIP-seq experiments target-
ing histone acetylation changes associated with GBM
development may be necessary. These findings are sub-
ject to further cross-validation and experimental investi-
gation. Besides genes, our approach can be applied to
identify microRNA modules which show strong associa-
tion with patient survival and the results can also shed
light on microRNA transcription regulation.
Conclusions
In this paper, we introduced eQCM algorithm for
mining dense network clusters in weighted graphs and
used this approach to identify 16 gene networks asso-
ciated with GBM prognosis on weighted gene co-expres-
sion network. Our results not only confirmed previous
findings including the importance of cell cycle and
immune response networks in GBM, but also suggested
important epigenetic events in GBM development and
prognosis.
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